Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Multicenter, Phase I Dose Escalation Study of MEN1309, a CD205 Antibody-Drug Conjugate,in Patients With CD205-Positive Metastatic Solid Tumors and Non-Hodgkin Lymphoma

Next Previous
X
Search
Trial Profile

Open-Label, Multicenter, Phase I Dose Escalation Study of MEN1309, a CD205 Antibody-Drug Conjugate,in Patients With CD205-Positive Metastatic Solid Tumors and Non-Hodgkin Lymphoma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEN 1309 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Diffuse large B cell lymphoma; Gastric cancer; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms CD205SHUTTLE
  • Sponsors Menarini

    • Most Recent Events

    • 06 Mar 2020 Status changed from recruiting to discontinued.
    • 05 Jun 2018 The enrollment began in October 2017 in European sites; up to date 3 cohort levels have been achieved as per trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top